芦可替尼乳膏治疗皮炎效果怎么样?

Ruxolitinib cream has a good effect in treating dermatitis. It is the first topical Janus kinase (JAK) inhibitor approved by the US FDA. It can significantly reduce skin inflammation and itching in the treatment of mild to moderate atopic dermatitis. Ruxolitinib Cream is indicated for the short-term and non-ongoing chronic treatment of adolescents (age ≥12 years) and adults with mild to moderate atopic dermatitis (AD) who are not immunocompromised and are not adequately controlled by topical prescription therapies or when these therapies are not advisable. Ruxolitinib cream has dual antipruritic and anti-inflammatory effects in the treatment of atopic dermatitis. It is very effective in reducing skin thickening and itching by downregulating T helper (Th)2-driven inflammation.

Trial effect of ruxolitinib cream in the treatment of atopic dermatitis

In a Phase 2 study in adults with atopic dermatitis (AD), strong anti-inflammatory and antipruritic benefits were demonstrated. To evaluate the 8-week efficacy and safety of ruxolitinib cream in 2 phase 3 studies in patients with AD.

Test method

Study 1 (NCT03745638) and Study 2 (NCT03745651) evaluating topical ruxolitinib cream in atopic dermatitis enrolled patients ≥12 years of age, with atopic dermatitis duration of ≥2 years, an investigator global assessment score of 2/3, and 3%-20% of their body surface area affected. Patients were randomly assigned in a 2:2:1 ratio to receive 0.75% RUX cream, 1.5% ruxolitinib cream, or vehicle cream twice daily for 8 weeks. The primary endpoint was investigator's global assessment of treatment success at week 8 (investigator's global assessment score of 0/1 and ≥2-grade improvement from baseline).

Research results

In Studies 1 and 2 evaluating topical ruxolitinib cream in atopic dermatitis, 631 and 618 patients, respectively, were randomized (efficacy analysis 631/577). At week 8, significantly more patients achieved investigator-assessed overall treatment success using ruxolitinib 0.75% cream (50.0%/39.0%) and ruxolitinib 1.5% cream (53.8%/51.3%) than patients using the drug (15.1%/7.6%; P < .0001).

Pruritus was significantly reduced within 12 hours after the first application of ruxolitinib 1.5% cream (P < .05). Application site reactions are uncommon (less than 1%), and ruxolitinib cream reactions are lower compared with drug drugs and have no obvious clinical manifestations.

Test conclusion

Ruxolitinib cream has anti-inflammatory and rapid itching effects, is more effective than medications, and is well tolerated.

Ruxolitinib cream side effects

Common symptoms of ruxolitinib cream include pain or swelling in the nose or throat (nasopharyngitis), diarrhea, bronchitis, ear infections, increased eosinophil (a type of white blood cell) count, urticaria, folliculitis, tonsillitis, runny nose, etc. The patient's physical condition and condition are different, and the side effects after taking the drug are also different. However, it should be noted that ruxolitinib cream may cause serious infections, mortality, malignant tumors, major adverse cardiovascular events, and thrombosis.

Side effects of ruxolitinib cream

1. Rest and maintain adequate fluid intake: Rest can help the body recover, and adequate fluid intake can help maintain water balance and promote physical recovery.

2. Drug treatment: For symptom relief, you can try over-the-counter drugs, such as antipyretics (for fever), analgesics (for pain), anti-allergic drugs (for urticaria), etc. But be sure to follow the medicine instructions and seek medical advice.

3. Gargling with warm water and gargling with salt water: For sore throat and tonsillitis, gargling with warm water can relieve inflammation; while rinsing with salt water can clean the nasal cavity and reduce nasal congestion and runny nose.

4. Maintain indoor air circulation: Maintaining indoor air circulation can reduce allergens and harmful substances in the air and help relieve symptoms.

If the side effects of ruxolitinib cream continue to be severe, you need to contact your doctor in time for symptomatic treatment. For specific treatment methods for these symptoms, please consult your doctor for evaluation and diagnosis to develop the most appropriate treatment plan.

Recommended related articles:

References

Papp K, Szepietowski JC, Kircik L, Toth D, Eichenfield LF, Leung DYM, Forman SB, Venturanza ME, Sun K, Kuligowski ME, Simpson EL. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies. J Am Acad Dermatol. 2021 Oct;85(4):863-872. doi: 10.1016/j.jaad.2021.04.085. Epub 2021 May 4. PMID: 33957195.